Metabolic Syndrome and Endocrine Disrupting Chemicals: An Overview of Exposure and Health Effects

Elsi Haverinen, Mariana F. Fernandez, Vicente Mustieles and Hanna Tolonen
Additional contact information
Elsi Haverinen: Department of Public Health and Welfare, Finnish Institute for Health and Welfare (THL), 00300 Helsinki, Finland
Mariana F. Fernandez: Department of Radiology, School of Medicine, University of Granada, 18016 Granada, Spain
Vicente Mustieles: Department of Radiology, School of Medicine, University of Granada, 18016 Granada, Spain
Hanna Tolonen: Department of Public Health and Welfare, Finnish Institute for Health and Welfare (THL), 00300 Helsinki, Finland

IJERPH, 2021, vol. 18, issue 24, 1-19

Abstract: Increasing prevalence of metabolic syndrome (MetS) is causing a significant health burden among the European population. Current knowledge supports the notion that endocrine-disrupting chemicals (EDCs) interfere with human metabolism and hormonal balance, contributing to the conventionally recognized lifestyle-related MetS risk factors. This review aims to identify epidemiological studies focusing on the association between MetS or its individual components (e.g., obesity, insulin resistance, diabetes, dyslipidemia and hypertension) and eight HBM4EU priority substances (bisphenol A (BPA), per- and polyfluoroalkyl substances (PFASs), phthalates, polycyclic aromatic hydrocarbons (PAHs), pesticides and heavy metals (cadmium, arsenic and mercury)). Thus far, human biomonitoring (HBM) studies have presented evidence supporting the role of EDC exposures on the development of individual MetS components. The strength of the association varies between the components and EDCs. Current evidence on metabolic disturbances and EDCs is still limited and heterogeneous, and mainly represent studies from North America and Asia, highlighting the need for well-conducted and harmonized HBM programmes among the European population. Rigorous and ongoing HBM in combination with health monitoring can help to identify the most concerning EDC exposures, to guide future risk assessment and policy actions.

Keywords: metabolic syndrome; endocrine disrupting chemicals; human biomonitoring; HBM4EU; obesity; insulin resistance; diabetes; dyslipidemia; hypertension (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2021
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (2)

Downloads: (external link)
https://www.mdpi.com/1660-4601/18/24/13047/pdf (application/pdf)
https://www.mdpi.com/1660-4601/18/24/13047/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:18:y:2021:i:24:p:13047-:d:699637

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().